TITLE: SIGMA METRICS ASSESSMENT AS QUALITY IMPROVEMENT METHODOLOGY IN A CLINICAL CHEMISTRY LABORATORY

Dr Monika Garg¹, Dr Neera Sharma², Dr Saswati Das³

¹Senior Resident, Biochemistry, ABVIMS & DR RML Hospital, New Delhi.

²Professor & Head of Department, Biochemistry, ABVIMS & DR RML Hospital, New Delhi.

³Specialist, Grade, Biochemistry, ABVIMS & DR RML Hospital, New Delhi

Corresponding Author: **Dr Saswati Das**, Specialist, Biochemistry, ABVIMS & DR RML Hospital, New Delhi

Email: drsaswatidas@gmail.com

ABSTRACT

Background:- The concept of sigma metrics & lean six sigma is well known in the field of healthcare. However not many labs utilize the six sigma metrics for maintenance of high quality laboratory performance. A minimum value of 3 σ is desired in any clinical laboratory & values of $\sigma \geq 6$ are regarded as gold standard for obtaining high quality lab reports.

Aims & Objectives:- To calculate bias, cv & sigma metrics from the IQC & EQC data in order to ascertain extent of quality management in our lab.

Materials & Methods:- An extensive study of sample processing and quality practices was carried out in the Central Laboratory of Department of Biochemistry; PGIMER & Dr. RML Hospital, New Delhi; from Feb 2020 to July 2020. The IQC used (both level I & level II) were from Biorad Laboratories India (lyphochek assayed chemistry control) & the EQC used was from Randox Laboratories, UK. All the controls were run on Beckman Coulter clinical chemistry analyser AU 680. Total 14 clinical parameters were analysed & subsequently; Mean, S.D., CV, bias & σ were calculated through their respective formulas.

Results:- Sigma level was more than 6 for both levels of IQC was observed for Amylase. It indicates world class performance. Total bilirubin, AST, Triglyceride & HDL depicted σ values between 3.1 – 6 for both L₁ & L₂. Iron showed σ value of 5.5 in L₁ whereas it was 3.78 in L₂.

Conclusion:- Sigma metrics in clinical laboratory is an essential technique to ascertain poor assay performance, along with assessment of the efficiency of existing laboratory process.

Keywords:- Six sigma, Coefficient of variation, Total allowable error, Bias, Quality control

Introduction:-In any Healthcare Laboratory, the term “quality” is defined as conformance to the requirements of users (nurses & physicians) or customers (patients or other parties who pay the bills) & the satisfaction of their needs & expectations.¹

Certain good quality indicators like reduced number of repeats & reruns; reduced time for sample transportation and storage ultimately leading to decreased Turn Around Time (TAT) etc. signify the good quality of Lab reports.^{2,3} A good quality laboratory performance is depicted in the test reports it generates and is also equally reflected in the Quality Controls performed as its performance checks. Besides Internal Quality Control (IQC) and External Quality Control (EQC); their exhaustive interpretation has become quite indispensable in the present scenario. This can be carried out by using the concept of “Six Sigma” and “Lean Six Sigma”. In spite of being introduced in Motorola since 1986; “Six Sigma” methodology was adopted in laboratory medicine in the year 2000.⁴ This concept basically revolves around decreasing the “non-value-adding” steps of a process and to enhance the quality of the process by reducing errors associated with it.⁵

Sigma (σ) reflects the Defects or errors per Million Opportunities (DPMO). The sigma refers to the number of SDs from the mean a process can be, before it is outside the acceptable limits. The process having 6σ is considered extremely precise, having only 3.4 DPMO.

Materials & Methods:-An exhaustive study of sample processing and quality control procedures was carried out in the Central Laboratory of Department of Biochemistry; PGIMER & Dr. RML Hospital, New Delhi; from Feb 2020 to July 2020. The corresponding data was collected and analysed subsequently.

The IQC used (both level I & level II) were from Biorad Laboratories India (lyphochek assayed chemistry control) & the EQC used was from Randox Laboratories, UK. All the controls were run on Beckman Coulter clinical chemistry analyser AU 680. On each day,

both the levels of IQC were run & analysed. The patients' samples were run & reported only if the IQC came within the acceptable range following the Westgard rules.

The parameters which were analysed include Glucose, Urea, Total bilirubin, AST, ALT, total protein, albumin, cholesterol, triglyceride, High Density Lipoprotein (HDL), sodium, potassium, amylase & Iron.

By using IQC data; Mean & S.D. were determined. Subsequently, CV% (coefficient of variation) was calculated using the following formula:-

$$\text{CV\%} = \text{SD} \times 100 / \text{Lab Mean}$$

Further; Bias was ascertained by employing RIQAS with the following formula:-

$$\text{Bias (\%)} = | (\text{Mean of all laboratories using same instrument \& method} - \text{Our Laboratory Mean}) | / (\text{Mean of all laboratories using same instrument \& method}) \times 100$$

Values for TE_a (Total allowable Error) were taken from **CLIA** (Clinical Laboratories Improvement Act) guidelines

Finally, Sigma metrics (σ) was determined using following equation:-

$$\text{Sigma metrics } (\sigma) = (\text{TE}_a - \text{Bias}) / \text{CV}$$

The methodology employed to implement Lean Six Sigma in our Central Laboratory was DMAIC i.e. Define, Measure, Analyse, Improve and Control. It means “defining” the problem due to which our results are deviating from the range of established standards. It also includes defining the resources which may be required to solve the problem.⁶

Subsequently, in order to solve the problem; its extent was “measured”, through collection of pertinent data & retain it in a more presentable form e.g. collection of IQC & EQC data & calculating CV% & Bias% respectively from it.^{6,7}

Further, the data was “analysed” in order to ascertain the root causes of the defect or problem. In this phase; the differences between our results & the target values are estimated along with determination of their possible causes.⁸

After that, the root causes were eliminated by implementing certain corrective measures in accordance with Westgard sigma rules⁹ to “improve” the process performance. Once the

defect is rectified; certain preventive measures were also taken in order to “control” or check that such problem or defect should not occur in future.

In order to eliminate any errors and wasteful steps during sample processing; every step of sample processing was carefully reviewed and monitored. Many corrective measures were taken to reduce errors at pre-analytical; analytical and post-analytical phases in order to reduce TAT and improve quality of sample processing.

Results & Observations :

In the present study IQC & EQC data of 6 months (February 2020 to July 2020) was collected & compiled in excel sheets to calculate Mean, S.D., CV%, Bias and Sigma Metrics for 14 different parameters. While evaluating IQC, it can be observed that only Total bilirubin, ALT & HDL had CV% >5 in L₁ and rest all parameters showed CV% <5 (Table 1).

As far as L₂ is concerned, except for HDL (CV% >5); rest all parameters had CV% <5.

Now taking EQC into consideration, out of all the measured parameters, average bias of sodium was minimum (0.85) whereas Triglyceride & HDL had bias >5. (Table 2)

As seen in (Table 3) average σ value for amylase is maximum for both levels of IQC.

According to (Table 4); $\sigma > 6$ for both levels of IQC was observed for Amylase. It indicates world class performance of this analyte. Further, 4 parameters namely Total bilirubin, AST, Triglyceride & HDL depicted σ values between 3.1 – 6 for both L₁ & L₂. Iron showed σ value of 5.5 in L₁ but 3.78 in L₂. Remaining all parameters had $\sigma < 3$ in L₁. As far as L₂ is concerned, besides ALT which had σ value 4.24; rest all analytes had $\sigma < 3$.

Discussion :- In the process of maintaining high laboratory quality standards, six sigma is regarded as an indispensable tool. The concept of Lean six sigma aims at reducing the wasteful activities during sample processing. When sigma metrics is ≥ 6 , then the process is said to have only 3.4 DPMO & it is regarded as the “World Class Quality”.

Although achievement of sigma metrics value 6 or more is not easy, but with appropriate precautions to minimise the errors associated with sample processing (at pre-analytical, analytical & post analytical phases); this goal can be approached.

In the present study, IQC & EQC data of 6 months (February 2020 to July 2020) was used to calculate Mean, S.D., CV%, bias & sigma metrics of 14 analytes. The two entities, S.D. & CV% are used to measure the extent of deviation & variation respectively of IQC test result

with respect to its mean. In general, CV% is the favoured mode of presentation. If CV is less than 5%, then the particular method used for determination of an analyte's concentration is said to have a very good performance & precise.^{7,10,13} It can be visualised from Table 1 & Table 2 that except for HDL, (CV% > 5 in both L₁ & L₂) along with Total bilirubin & ALT (having CV% > 5 in L₁); rest all parameters depicted CV < 5%. This clearly indicates that our lab has achieved high level of precision in remaining 11 analytes.

Another important calculated index in the present study is bias% by using the EQC data. As per the definition, the term "bias" implies any discrepancy between the results of our lab & the peer group labs employing the same instrument & methodology.^{7,11} This means that we should try to minimise the bias, in order to decrease the differences between the lab results. Out of all the parameters measured in the present study, Sodium had the minimum bias of 0.85 (Table 2) while rest analytes had bias < 5% (except HDL & Triglyceride). This shows high degree of accuracy in our lab results.

TE_a is the sum of random error (imprecision) and systematic error (bias or inaccuracy).^{7,12,13} Also, this term encompasses the pre-analytical variations, biologic variations etc that leads to variability in patients' results.

In the present study; $\sigma > 6$ for both levels of IQC was observed for Amylase (Table 4). Hence it required only 1_{3s} Westgard sigma rule to be followed since it was showing excellent performance. Among others, Total bilirubin, AST, Triglyceride & HDL depicted σ values between 3.1 – 6 for both L₁ & L₂ with Iron showing σ value of 5.5 in L₁ and 3.78 in L₂. It implies Westgard sigma multirole application is needed for such parameters. For parameters having σ values between 5 to 6; three rules namely 1_{3s}, 2_{2s}, and R_{4s} are needed. 4-sigma quality requires addition of a 4th rule and implementation of a 1_{3s}/2_{2s}/R_{4s}/4_{1s} multirole. Those parameters having $\sigma < 3$ requires extensive evaluation in terms of reducing analytical bias & imprecision.^{9,11,12,14}

Conclusion:- Sigma metrics in clinical laboratory is a vital methodology to identify & correct any deviation of lab results from the prescribed standards. It can help us ascertain poor assay performance along with assessment of the efficiency of existing laboratory process. The unnecessary & time consuming wasteful additional steps can be eliminated using the concept of sigma metrics & lean six sigma. This will decrease the TAT & help in dispatching good quality reports for better patient management. Further, sigma metrics can help in devising appropriate strategies for the judicious utilisation of IQC & EQC in a large sized clinical laboratory.

REFERENCES

- 1) Westgard JO, Klee GG. Quality management. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry. 5th ed. Philadelphia: Saunders; 2012. p. 163.
- 2) Pati HP, Singh G. Turnaround Time (TAT): Difference in Concept for Laboratory and Clinician. Indian J Hematol Blood Transfus. 2014 Jun;30(2):81–84.
- 3) Coetzee LM, Cassim N, Glencross DK. Weekly laboratory turn-around time identifies poor performance masked by aggregated reporting. Afr J Lab Med. 2020; 9(1): 1102.
- 4) Peng S, Zhang J, Zhou W, Mao W, Han Z. Practical application of Westgard Sigma rules with run size in analytical biochemistry processes in clinical settings. J Clin Lab Anal. 2021 Mar;35(3).
- 5) Zepeda-Lugo C, Tlapa D, Baez-Lopez Y, Limon-Romero J, Ontiveros S, Perez-Sanchez A, et al. Assessing the Impact of Lean Healthcare on Inpatient Care: A Systematic Review. Int J Environ Res Public Health. 2020 Aug; 17(15): 5609.
- 6) Smętkowska M, Mrugalska B. Using Six Sigma DMAIC to improve the quality of the production process: a case study. Procedia - Social and Behavioral Sciences. 2018; 238:590 – 596.
- 7) Singh B, Goswami B, Gupta VK, Chawla R, Mallika V. Application of sigma metrics for the assessment of quality assurance in clinical biochemistry laboratory in India: a pilot study. Indian J Clin Biochem. 2011;26:131-135.
- 8) Heher YK. A brief guide to root cause analysis. Cancer Cytopathol. 2017;125:79-82.
- 9) Westgard JO, Bayat H, Westgard SA. Planning risk-based SQC schedules for bracketed operation of continuous production analyzers. Clin Chem. 2018;64:289-296.
- 10) Suresh BG, Suneetha R. Evaluation of quality assurance in a new clinical chemistry laboratory by Six Sigma metrics. J Clin Diagn Res. 2019;13:BC04-BC07.

- 11) Kumar BV, Mohan T. Sigma metrics as a tool for evaluating the performance of internal quality control in a clinical chemistry laboratory. J Lab Physicians. 2018;10:194-199.
- 12) Shah S, Saini R, Singh SB, Aggarwal O, Goel AK. Six Sigma Metrics and Quality Control in Clinical Laboratory. Int J Med Res Rev 2014;2(2):140-149.
- 13) El Sharkawy R, Westgard S, Awad AM, Ahmed AKOI, Iman EH, Gaballah A, et al. Comparison between sigma metrics in four accredited Egyptian medical laboratories in some biochemical tests: an initiative towards sigma calculation harmonization. Biochem Med (Zagreb). 2018;28(2):020711.
- 14) : Zhou B, Wu Y, He H, Li C, Tan L, Cao Y. Practical application of Six Sigma management in analytical biochemistry processes in clinical settings. J Clin Lab Anal. 2020 Jan; 34(1): e23126.

Tables of six sigma article

Table 1. CV% calculated from Internal Quality Control L₁ & L₂ from February 2020 to July 2020 (6 months).

	L ₁							L ₂						
Parameter	Feb	March	April	May	June	July	Average	Feb	March	April	May	June	July	Average
Glucose	2.43	1.78	2.18	3.76	4.81	4.29	3.21	2.46	1.63	2.68	4.54	5.51	3.78	3.43
Urea	2.86	4.22	3.77	1.52	3.26	4.32	3.32	3.08	2.77	3.5	2.64	3.35	4.8	3.36
Total Bilirubin	4.83	3.88	5.36	2.04	5.63	9.03	5.13	2.22	4.44	4.54	2.94	4.09	6.79	4.17
AST	3.28	4.16	3.88	2.62	4.27	4.75	3.83	2.14	2.01	3.12	2.87	3.48	4.39	3.0
ALT	8.09	9.19	7.12	3.75	5.06	5.24	6.41	2.94	2.93	5.91	3.09	3.26	4.64	3.8
Total Protein	3.12	2.27	3.15	4.01	3.79	3.35	3.28	3.39	2.55	4.21	5.17	4.05	3.43	3.8
Albumin	2.16	1.96	2.27	1.7	3.85	5.59	2.92	2.55	1.74	2.89	3	3.36	5.49	3.17
Cholesterol	2.43	4.36	3.29	2.31	2.31	3.59	3.05	2.03	2.42	2.86	2.6	2.14	4.67	2.79
Triglyceride	6	2.35	4.14	2.66	4.06	5.03	4.04	5.52	2.68	3.04	3.67	5.8	6.21	4.49
HDL	4.48	5.98	6.42	5.25	6.49	5.14	5.63	3.53	4.09	5.67	6.14	6.78	6.25	5.41
Sodium	1.34	1.19	1.72	1.31	1.31	2.19	1.51	1.16	1.31	2.52	1.56	1.18	2.25	1.66
Potassium	1.53	1.71	2.08	1.87	1.53	2.46	1.86	1.28	1.33	2.77	1.51	1.58	2.54	1.84
Amylase	2.22	3.15	2.92	2.45	2.01	3.47	2.7	1.91	1.34	4.29	2.98	2.58	4.48	2.93
Iron	2.86	3.59	3.75	2.63	2.24	3.44	3.08	3.63	4.73	4.29	5.6	3.88	4.76	4.48

Table 2. Bias % calculated from RIQAS for 6 months (February 2020 to July 2020).

Parameter	Feb	March	April	May	June	July	Average
Glucose	1.36	3.98	1.32	6.17	3.14	3.61	3.26
Urea	0.07	0.9	4.9	0.68	3.65	3.15	2.22
Total Bilirubin	0	1.79	5.67	0	1.79	0.59	1.64
AST	2.78	0.76	3.3	2.44	3.57	10.08	3.82
ALT	0.83	2.9	2.2	9.09	2.24	6	3.87
Total Protein	2.63	1.72	9.09	3.45	0	0.87	2.96
Albumin	0.48	2.6	3.7	0	1.96	2.25	1.83
Cholesterol	5.24	6.01	2.75	2.09	4.56	3.49	4.02
Triglyceride	7.8	0.39	3.2	6.5	10.04	3.59	5.25
HDL	6.2	3.84	3.92	0	13.50	3.39	5.14
Sodium	1.29	0.97	0.06	1.05	0.8	0.98	0.85
Potassium	2.44	2.24	0.17	2.56	1.59	0.51	1.58
Amylase	5.06	1.28	0.64	0.61	1.54	0.12	1.54
Iron	4.09	4.04	3.01	2.74	2.09	2.48	3.07

Table 3. Sigma metrics calculated from Internal Quality Control L₁ & L₂ from February 2020 to July 2020 (6 months).

Parameter	L ₁							L ₂						
	Feb	March	April	May	June	July	Average	Feb	March	April	May	June	July	Average
Glucose	3.54	3.4	3.9	1	1.42	1.5	2.46	3.5	3.7	3.23	3.5	1.2	1.7	2.8
Urea	3.11	1.9	1.1	5.4	1.64	1.3	2.4	2.9	2.9	1.17	3.1	1.6	1.2	2.1
Total Bilirubin	4.3	4.7	2.7	9.7	3.2	2.1	4.45	8.9	4.1	3.1	6.7	5.3	3	5.18
AST	5.2	4.6	4.3	6.7	3.8	2.1	4.45	8.01	9.5	5.3	6.1	4.7	2.3	5.98
ALT	2.3	1.8	2.5	2.9	3.5	2.7	2.61	6.5	5.8	3	3.5	5.4	3	4.53
Total Protein	2.35	3.6	0.3	1.6	2.6	2.7	2.19	2.1	3.2	0.2	1.3	2.4	2.6	1.96
Albumin	4.4	3.8	2.8	5.8	2.1	1.4	3.38	3.7	4.3	2.2	3.3	3.6	1.4	3.08
Cholesterol	1.9	0.9	2.2	3.4	2.3	1.8	2.08	2.3	1.6	2.5	3	6.8	1.4	2.93
Triglyceride	2.8	10.4	5.3	6.9	3.7	4.2	5.55	3.1	9.1	7.1	8.6	6	4.6	6.41
HDL	5.2	4.4	4	5.7	2.5	5.2	4.5	6.7	6.4	4.6	4.9	2.4	4.2	4.86
Sodium	2.7	3.3	2.8	3	3.2	1.8	2.8	3.2	3.1	1.9	3.8	4.9	1.8	3.11
Potassium	2.3	2.2	2.8	1.8	2.8	2.2	2.35	2.8	2.8	2.1	5.6	4.8	2.1	3.36
Amylase	11.2	9.1	10	11.9	14.1	8.6	10.81	13.1	21.4	6.8	9.8	11	6.7	11.46
Iron	5.5	4.4	4.5	6.5	7.9	5.1	5.65	4.4	3.4	3.9	4	5.7	3.7	4.18

Table 4. Average Bias, Average CV% & sigma metrics calculated for 6 months for both levels of IQC (L₁ & L₂).

Parameter	TE _a %	Average Bias%	Average CV% (L ₁)	σ (L ₁)	Average CV% (L ₂)	σ (L ₂)
Glucose	10	3.26	3.21	2.09	3.43	1.96
Urea	9	2.22	3.32	2.04	3.36	2.01
Total Bilirubin	20	1.64	5.13	3.58	4.17	4.4
AST	20	3.82	3.83	4.22	3.0	5.39
ALT	20	3.87	6.41	2.51	3.8	4.24
Total Protein	10	2.96	3.28	2.14	3.8	1.85
Albumin	10	1.83	2.92	2.79	3.17	2.58
Cholesterol	10	4.02	3.05	1.95	2.79	2.14
Triglyceride	25	5.25	4.04	4.88	4.49	4.39
HDL	30	5.14	5.63	4.41	5.41	4.59
Sodium	5	0.85	1.51	2.74	1.66	2.5
Potassium	6	1.58	1.86	2.36	1.84	2.4
Amylase	30	1.54	2.7	10.5	2.93	9.71
Iron	20	3.07	3.08	5.5	4.48	3.78